Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LIGHTBEAM-U01 Substudy 01C: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors

Next Previous
Trial Profile

LIGHTBEAM-U01 Substudy 01C: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Patritumab Deruxtecan (Primary)
  • Indications Rhabdomyosarcoma
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Acronyms LIGHTBEAM-U01 Substudy 01C
  • Sponsors Merck Sharp & Dohme Corp.

Most Recent Events

  • 09 Jun 2025 Planned initiation date changed from 12 Jun 2025 to 26 May 2025.
  • 09 Jun 2025 Status changed from not yet recruiting to recruiting.
  • 08 May 2025 Planned initiation date changed from 22 May 2025 to 12 Jun 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top